SAN DIEGO--(BUSINESS WIRE)--SkinMedica, Inc. announced today that Mary M. Fisher has joined the Company as Chief Executive Officer.
Ms. Fisher was previously Chief Operating Officer at Acorda Therapeutics, a biotechnology company focused on developing products for the treatment of central nervous system disorders. During her seven years at Acorda, she also served as Executive Vice President of Commercial Operations and Vice President of Marketing and Strategic Planning. As Chief Operating Officer, she played a key role in Acorda’s success, including its successful IPO and the subsequent strong operating performance and impressive growth in shareholder value. Prior to Acorda, Mary was VP, Commercial Operations with Cephalon. Her earlier career includes positions with Immunex and Boehringer Ingelheim.
Rex Bright, the current President and CEO of SkinMedica, commented, “I’m delighted to welcome Mary to SkinMedica. She brings an impressive track record of accomplishment, with over 25 years of pharmaceutical and biotechnology industry experience. Mary is ideally suited to lead SkinMedica’s continued growth and development in the rapidly expanding dermatology and skincare markets. I look forward to working closely with her to achieve these objectives.” Mr. Bright will continue as President of SkinMedica, and a member of the Board of Directors, and will also consult closely with Ms. Fisher.
“I am excited by the opportunity to lead SkinMedica. I am extremely impressed by the quality of their pharmaceutical and aesthetic products, which are backed by strong science and solid clinical data,” said Ms. Fisher. “The Company already has a very strong management team, and I look forward working closely with them to help grow SkinMedica into one of the major dermatology and skincare companies worldwide.”
David F. Hale, SkinMedica’s Executive Chairman, stated, “Mary’s leadership and entrepreneurial skills, together with her long record of success in this industry, will serve SkinMedica well. We are confident that under Mary’s leadership we can continue to build one of the leading companies in our field.”
About SkinMedica
SkinMedica is a privately held pharmaceutical company marketing both prescription and aesthetic dermatology products. SkinMedica’s Desonate® (desonide) Gel 0.05% is indicated for the treatment of mild to moderate atopic dermatitis; EpiQuin® Micro (4% hydroquinone) cream is indicated for melasma and postinflammatory hyperpigmentation; VANIQA® (eflornithine hydrochloride) Cream, 13.9%, is the only FDA-approved prescription product for the treatment of unwanted facial hair in women; and NeoBenz® Micro Cream and NeoBenz® Micro SD (single dose) are the only benzoyl peroxide prescription products that contain a patented gradual-release formulation of benzoyl peroxide to treat acne. The company’s full line of physician-dispensed skin care products includes TNS Recovery Complex® with NouriCel-MD® to help improve the health and appearance of aging skin. SkinMedica is based in Carlsbad, California. For more information, visit www.skinmedica.com.
SkinMedica®, Desonate®, EpiQuin® Micro, NeoBenz® Micro, NouriCel-MD®, TNS Recovery Complex®, and VANIQA® are registered trademarks of SkinMedica, Inc.
Contacts
SkinMedica, Inc. Christina Balesteri, Human Resources 760-448-3622
